Xingxiang Yang

1.0k total citations
14 papers, 429 citations indexed

About

Xingxiang Yang is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Xingxiang Yang has authored 14 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 5 papers in Hepatology and 2 papers in Infectious Diseases. Recurrent topics in Xingxiang Yang's work include Liver Disease Diagnosis and Treatment (7 papers), Hepatitis B Virus Studies (5 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Xingxiang Yang is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Hepatitis B Virus Studies (5 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Xingxiang Yang collaborates with scholars based in China. Xingxiang Yang's co-authors include Bo Long, Lingxi Jiang, Bo Gong, Yi Shi, Li Jiang, Zhenglin Yang, He Lin, Hua Yu, Chunbao Xie and Hong Pu and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Journal of Affective Disorders.

In The Last Decade

Xingxiang Yang

14 papers receiving 420 citations

Peers

Xingxiang Yang
Pei Hua Lee Singapore
Dong Wei China
Stacey A. Rizza United States
Ann E. Woolley United States
John Davies United Kingdom
Negar Niki Alami United States
Pei Hua Lee Singapore
Xingxiang Yang
Citations per year, relative to Xingxiang Yang Xingxiang Yang (= 1×) peers Pei Hua Lee

Countries citing papers authored by Xingxiang Yang

Since Specialization
Citations

This map shows the geographic impact of Xingxiang Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingxiang Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingxiang Yang more than expected).

Fields of papers citing papers by Xingxiang Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingxiang Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingxiang Yang. The network helps show where Xingxiang Yang may publish in the future.

Co-authorship network of co-authors of Xingxiang Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Xingxiang Yang. A scholar is included among the top collaborators of Xingxiang Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingxiang Yang. Xingxiang Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Gao, Jie, et al.. (2025). The protection of nicotinamide riboside against diabetes mellitus-induced bone loss via OXPHOS. Bone. 193. 117411–117411. 1 indexed citations
2.
Tuo, Lin, et al.. (2024). Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study. Frontiers in Endocrinology. 15. 1315046–1315046. 2 indexed citations
3.
Liu, Yuqin, et al.. (2024). Association between triglyceride glucose index and cognitive decline: A meta-analysis. Journal of Affective Disorders. 359. 70–77. 12 indexed citations
4.
Yan, Liting, Lin Tuo, Tingting Luo, et al.. (2023). Cellular and molecular insights into incomplete immune recovery in HIV/AIDS patients. Frontiers in Immunology. 14. 1152951–1152951. 27 indexed citations
5.
Jiang, Hua, Yu Wang, Xingxiang Yang, et al.. (2020). A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV). Zhonghua jizhen yixue zazhi. 29(12). 1 indexed citations
6.
Xie, Chunbao, Lingxi Jiang, Guo Huang, et al.. (2020). Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. International Journal of Infectious Diseases. 93. 264–267. 247 indexed citations
7.
Xie, Wen, Yang Cao, Min Xu, et al.. (2017). Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Scientific Reports. 7(1). 10289–10289. 10 indexed citations
8.
Wu, Jiazhen, et al.. (2017). Differences in HBsAg and HBcAg expression in liver tissues between chronic hepatitis B patients with immunologic tolerance vs immune activity. World Chinese Journal of Digestology. 25(7). 620–620. 1 indexed citations
9.
Wang, Lu, Tao Wu, Jun Xi, et al.. (2016). NLRP3 Activation Was Regulated by DNA Methylation Modification duringMycobacterium tuberculosisInfection. BioMed Research International. 2016. 1–10. 56 indexed citations
10.
Jiang, Nan, Jian-Mei Lin, Gang Xu, et al.. (2016). Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B. Experimental and Therapeutic Medicine. 11(5). 1673–1677. 26 indexed citations
11.
Yang, Xingxiang, et al.. (2016). Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis. Saudi Journal of Gastroenterology. 22(4). 294–294. 24 indexed citations
12.
Yang, Xingxiang, et al.. (2014). Hepatic actinomycosis: Report of one case and analysis of 32 previously reported cases. World Journal of Gastroenterology. 20(43). 16372–16372. 20 indexed citations
13.
Yang, Xingxiang, Yuping Liu, Min Dai, & Xiaowei Li. (2010). Nonalcoholic fatty liver disease among adult health examination participants in Chengdu. 4(1). 22–24. 1 indexed citations
14.
Lin, Jian-Mei, et al.. (2009). [Comparison of liver pathohistological and clinical characteristics between chronic HBV carriers and chronic hepatitis B patients with mild elevation in ALT].. PubMed. 17(10). 735–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026